glp 1 agonists quizlet The GLP-1 and Obesity: How Diabetes Drugs are Changing Non-Diabetic Lives — tl;dr pharmacy Geriatrics - Endo, Rheum Flashcards

Partly through these actions, GLP-1 receptor agonism was shown to reduce cardiovascular disease (CVD) in people with T2D with previous CVD or at high-risk thereof

Drug safety isnt just about innovation

Clinical breakthroughs, shifting policies, and changing market dynamics are converging to redefine obesity care globally

Moreover, the combined GLP-1 mechanisms of weight loss and delayed carbohydrate absorption may also be the key drivers of remission of type 2 diabetes and reduced cardiovascular events found by GLP-1 analogues.

Includes PREDIMED data and EU health claim context.

Results Reducing dose frequency does not commensurately reduce weight loss